Rheumatoid Arthritis

RA drug shows superiority compared with adalimumab and placebo.

Patients seeking treatment with the same drugs may face different out-of-pocket costs.

Azathioprine exposure linked to myeloid neoplasm.

Study opens doors for more precise RA treatments.

Top articles of the week on Specialty Pharmacy Times.

Aerobic exercise increases hematologic indices in patients with RA.

Smoking is a risk factor for breaking tolerance to multiple autoantigens in RA.

Scientists used a novel approach for imaging the movement of immune cells in mouse models of RA.

Targeting immune cells entering joints may prevent inflammatory arthritis.

TNFis improve the burden of comorbidity associated with RA.

Incidence of sleep apnea is 75% higher in patients with rheumatoid arthritis.

Certain factors influence the choice of the biologic drug in RA.

Humira is currently approved to treat rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

Treatment for rheumatoid arthritis carries numerous difficulties, from physical challenges to gaining access to new drugs.

Anti-TNFs reduce severity and incidence of myocardial infarction in RA patients.

Investigators identify factors that contribute to the chronic nature of autoimmune diseases.

Children exposed to rheumatoid arthritis in utero saw elevated early and late childhood epilepsy risk.

The FDA only approved 22 new drugs in 2016, the lowest amount in years.

Tracking a particular anti-tumor necrosis factor (TNF) through the body can help determine an effective RA dose.

Study findings may improve the prevention and treatment of rheumatoid arthritis.

When treatment with DMARDs does not work, biologic agents are used to treat RA.

Increased presence of myocardial inflammation in patients with rheumatoid arthritis could be treated with non-TNFi biologic disease modifying anti-rheumatic drugs.

The proportion of specific inflammatory proteins can influence treatment outcomes.

Patients with RA may be overwhelmed by information about disease-modifying antirheumatic drugs.

There is a need for the surgeons and prescribing rheumatologists to jointly address complications they may cause in RA patients.

The relationship between heart disease and rheumatoid arthritis needs deeper examination.

The amount of information patients receive about disease-modifying anti-rheumatic drugs may overwhelm their memory.

New research is needed to determine proper diagnostic measurements for sarcopenia.

Distinct subsets of synovial fibroblasts in rheumatoid arthritis development identified.

Top news of the week on Specialty Pharmacy Times.